

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.



June 26, 2026

NEWS RELEASE

Company name: TSUMURA & CO.
 Listing: TSE Prime Market
 Securities code: 4540
 URL: <https://www.tsumura.co.jp>
 Representative: Terukazu Kato, President, Representative Director and CEO
 Inquiries: Makoto Kitamura, Head of Corporate Communications Dept.
 Telephone: +81-3-6361-7100

Notice Regarding Change in Representative Director (Additional Appointment)

TSUMURA & CO. (the “Company”) announce that at the extraordinary board of directors meeting held on June 26, 2026, we resolved to make changes to the representative director (additional appointment).

1. Reason for change

To further strengthen the management structure and establish a rapid decision-making system.

2. Details of the change

Name	New position	Previous position
Kei Sugii	Representative Director, COO and President, Prescription Pharmaceuticals Company	Director, COO and President, Prescription Pharmaceuticals Company

3. Career Summary of the new Representative Director

Name	Kei Sugii	
Date of birth	December 16, 1969	
Number of Company shares held	10,900 shares	
Career Summary	April 1994	Joined Mitsubishi Petrochemical Engineering Corporation (Currently Mitsubishi Chemical Engineering Corporation)
	January 2006	Joined Accenture Japan Ltd.
	May 2009	Joined TSUMURA & CO.
	April 2013	Head of Logistics Planning Department
	April 2016	Head of SCM Planning Department
	April 2017	General Manager of the Company, CEO of SHENZHEN TSUMURA MEDICINE CO., LTD.
	April 2018	General Manager of the Company, Chairman and CEO of SHENZHEN TSUMURA MEDICINE CO., LTD.
	April 2020	Executive Officer, Production Division General Manager of the Company
	April 2022	Co-COO
	June 2022	Director Co-COO
	April 2026	Director, COO and President, Prescription Pharmaceuticals Company
	June 2026	Representative Director, COO and President, Prescription Pharmaceuticals Company (incumbent)

4. Date of change
June 26, 2026